Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer, Sanford-Burnham in Diabetes Discovery Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Pfizer, Sanford-Burnham in Diabetes Discovery Pact

Aim to develop new therapeutics for complications of obesity and diabetes

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanford-Burnham Medical Research Institute and Pfizer have entered into a three-year collaboration to identify new therapeutic targets for preventing and treating complications of obesity and diabetes using novel screening tools, including systems-biology approaches and technologies developed at Sanford-Burnham.
 
Sanford-Burnham and Pfizer will collaborate to identify and validate new targets for drug discovery. Investigators will use Sanford-Burnham’s Conrad Prebys Center for Chemical Genomics to screen for new targets using Pfizer’s investigational compounds, as well as evaluate compounds previously identified from the NIH chemical library.
 
“Diabetes presents an enormous public health burden. There is an acute need to translate innovative science into potential new medicines for people living with this debilitating disease,” said Tim Rolph, vice president and head of Cardiovascular and Metabolic Diseases Research Unit at Pfizer. “Pfizer’s collaboration with Sanford-Burnham to use their cutting-edge screen designs is an example of our strategy to work with academic innovators to discover novel therapeutics for prevention and treatment of diabetes.”
 
“This important collaboration focuses our tremendous scientific and translational firepower on a major medical problem, complications of obesity-related diabetes. Working with Pfizer, we can more quickly bridge the gap between basic and translational research,” said Stephen Gardell, Ph.D., senior director of scientific resources at Sanford-Burnham Medical Research Institute at Lake Nona.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics